Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04380-z
As presented at the 2026 AACR Annual Meeting: in a phase 1b trial, patients with microsatellite-stable colorectal cancer received a FAP-4-1BB ligand together with the CEA-directed T cell engager cibisatamab; the treatment was safe, and biomarker analysis showed induction of immunity in line with the biological rationale.
